2010 Annual Scientific Meeting and Exposition 2010 Annual ...

MAY 1PostersSaturday AfternoonPO-26: 3PO-27: 3PO-28: 3PO-29: 3PO-30: 3Differences between Two Fixed-Dose ofCombinations: Enalaprilo Plus Lercanidipine orFelodipine Plus Metoprolol on Central Pressure andAugmentation IndexRicardo M. Cabrera Sole, 1 Santiago Garcia Ruiz, 1Caridad Turpin Lucas, 1 Rafael Gil Landa, 1 JuanCañas, 2 Manuel Aguilera Saldaña. 1 1 University GeneralHospital of Albacete, Albacete, Albacete, ES and2 Health Center no 2 of Albacete, Albacete, Albacete,ES.A Fixed-Dose Combination of OlmesartanMedoxomil (OM), Amlodipine (AML), andHydrochlorothiazide (HCTZ): Use of Modeling andSimulation to Support an Understanding of theDose Response of Intermediate Dose CombinationsNot Included in the Pivotal Phase 3 StudyTimothy J. Carrothers†, 1 Michelle Green, 1 HelenMoore, 1 Shashank Rohatagi, 2 SaeHeum Song, 2 JamesLee, 2 Antonia Wang, 2 Reinilde Heyrman, 2 Daniel E.Salazar. 2 1 Pharsight, US and 2 Daiichi Sankyo PharmaDevelopment, US.Pharmacokinetic Interaction between Simvastatinand Diltiazem in RatsDong-Hyun Choi, Sung-Il Ha, Young-Youp Koh,Kyoung-sig Chang, Soon-Pyo Hong, Joong-WhaChung. College of Medicine, Chosun University,Gwangju, KR.Incidence of Hyperkalemia with Aliskiren/ValsartanCombination in Hypertensive Patients with Mildto Moderate Renal Impairment and Patients withNormal Renal Function: A 54 Week RetrospectiveAnalysisSteven G. Chrysant†, 1 Alexander Murray, 2 UtaHoppe, 3 Dan Dattani, 4 Samir Patel, 5 AnastasiaLesogor, 6 Melanie Wright, 6 Jack Zhang. 5 1 Universityof Oklahoma, US; 2 PharmQuest, US; 3 Universityof Cologne, DE; 4 Prairie Clinical Research Groupand University of Saskatchewan, CA; 5 NovartisPharmaceuticals Corporation, US and 6 NovartisPharma AG, CH.Efficacy and Safety of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ) in Patientswith Hypertension: Analysis by Age and GenderSteven G. Chrysant†, 1 Michael Melino, 2 VictorFernandez, 2 James Lee, 2 Reinilde Heyrman. 21 Oklahoma Cardiovascular and Hypertension Centerand University of Oklahoma College of Medicine, USand 2 Daiichi Sankyo, Inc, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track108